---
title: "阿斯利康在京启用全球战略研发中心"
description: "从阿斯利康获悉，其在京正式启用全新全球战略研发中心。该研发中心为阿斯利康全球第六个、在华第二个战略研发中心，也是阿斯利康 25 亿美元在华投资计划的核心项目。据悉，全球研发北京战略中心拥有人工智能和数据科学中心，旨在加速药物早期研究成果向临床开发转化。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/262725487.md"
published_at: "2025-10-25T09:47:52.000Z"
---

# 阿斯利康在京启用全球战略研发中心

> 从阿斯利康获悉，其在京正式启用全新全球战略研发中心。该研发中心为阿斯利康全球第六个、在华第二个战略研发中心，也是阿斯利康 25 亿美元在华投资计划的核心项目。据悉，全球研发北京战略中心拥有人工智能和数据科学中心，旨在加速药物早期研究成果向临床开发转化。

从阿斯利康获悉，其在京正式启用全新全球战略研发中心。该研发中心为阿斯利康全球第六个、在华第二个战略研发中心，也是阿斯利康 25 亿美元在华投资计划的核心项目。据悉，全球研发北京战略中心拥有人工智能和数据科学中心，旨在加速药物早期研究成果向临床开发转化。

### Related Stocks

- [AZN.US - 阿斯利康](https://longbridge.com/zh-CN/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Deutsche Bank  Keeps Their Sell Rating on AstraZeneca (AZN) | Deutsche Bank analyst Emmanuel Papadakis has maintained a Sell rating on AstraZeneca (AZN) with a price target of £115.0 | [Link](https://longbridge.com/zh-CN/news/276058097.md) |
| SLE and LN market expected to reach $5.9bn across 7MM by 2034 | A significant growth in the systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major ma | [Link](https://longbridge.com/zh-CN/news/276212995.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/zh-CN/news/276017486.md) |
| 11:23 ETAI in Biotechnology Market Size to Reach USD 1,971 Million by 2031 \| Valuates Reports | The global AI in Biotechnology market is projected to grow from USD 1,033 million in 2024 to USD 1,971 million by 2031,  | [Link](https://longbridge.com/zh-CN/news/276147064.md) |
| Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins | Nuclera and leadXpro have announced a partnership to enhance structure-based drug design for complex membrane proteins.  | [Link](https://longbridge.com/zh-CN/news/276109364.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。